In a sneak peak of everyone’s favorite collegially contentious Midyear session – Therapeutic Debates – Karen Whalen sits down with SCSS Educational Steering Committee members Kellie Goodlet, Amy Sipe, and Jessica Star to preview this can’t-miss educational session. This year’s debates are management of patients with penicillin allergy, provision of safe supply to patients with opioid use disorder, and monitoring of anti-Xa levels in patients receiving DOAC therapy.  

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Tom and Jillanne discuss recent conversations ASHP has had with the U.S. Department of Health & Human Services regarding the role of pharmacists in primary care. We touch on the types of services pharmacists are providing and highlight the pressing need for reimbursement and residency training support to sustain those models, and discuss the importance of partner organizations to our overall advocacy strategy.  

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Maintaining wellness while pursuing your Doctor of Pharmacy degree can be challenging. To address this, Student Societies of Health-System Pharmacists (SSHPs) are actively promoting wellbeing and resilience within their chapters. Through this podcast, we hope to highlight examples of how to incorporate wellness and wellbeing into SSHP initiatives, as well as share some tips on how to foster and sustain well-being and resilience during pharmacy school.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

The opioid epidemic is a dynamic multi-layered situation with regulatory changes affecting patients and providers in a variety of ways.  Although many regulation changes were designed with the best intentions, unintended consequences have surfaced in acute pain management for pediatric patients.  This podcast will discuss some of the implications and safety issues while providing information regarding appropriate pediatric medication therapy.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode features highlights from the 2021 Midyear Clinical Meeting where content matter experts from the Clinical Specialists and Scientists review the pharmacokinetic and pharmacdynamic characteristics a pharmacist must take into consideration when designing.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This session from the 2021 Midyear Clinical Meeting compares the advantages and disadvantages of continuing buprenorphine for opioid use disorder in patients with acute patients.  

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

USP recently published final revisions to the nonsterile compounding chapter and the sterile compounding chapter . ASHP Senior Director of Pharmacy Practice and Quality Michael Ganio discusses the revisions, what to expect before the chapters become official, and implications for chapter with compounding expert Patti Kienle. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast focuses on lessons learned from two PGY-1 pharmacists who have both matched to a PGY-2 program. Speakers will discuss how they decided to pursue a PGY-1, how the process differs from the PGY-1 application/interview process, and ultimately how they decided where they wanted to go. This Podcast episode will help future PGY1 residents prepare for the process of identifying and applying to PGY-2 programs.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Faculty from our Summer Meeting symposium on COVID-19 in the immunocompromised population discuss new information and recommendation updates that have occurred since their initial presentation.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this feature from the 2021 Midyear Clinical Meeting, our content matter experts share updates from the REDUCE-IT and STRENGTH trials and the role current therapies, as well as new and emerging therapies, play in managing dyslipidemia.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.